Cleveland Clinic | Strategic Alliance Partners

Aaron Gerds, MD, discusses the adverse event anemia in patients with myelofibrosis.

A prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.

Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms through the use of JAK-STAT pathway.

Megan Kruse, MD, discusses how to converse with patients with breast cancer about implementing biosimilars in treatment.

Gregory M. M. Videtic, MD, CM, FRCPC, discusses ongoing developments with immunotherapy in stage III non–small cell lung cancer.

Pradnya D. Patil, MD, FACP, discusses the implications of these trials and the growing role of immunotherapy in lung cancer.

Humberto Choi, MD, discusses using low-dose CT scans to screen patients with a high-risk of developing lung cancer.

Shilpa Gupta, MD, discusses the challenges of identifying predictive biomarkers in bladder cancer.

Davendra Sohal, MD, MPH, discusses the SWOG S1505 data and other emerging areas of research in pancreatic cancer.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses challenges with biomarkers in renal cell carcinoma (RCC).

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, and professor of medicine, Cleveland Clinic Lerner College of Medicine, discusses improving access to cancer therapy with biosimilars.

Brian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.

Davendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses managing the toxicity of pembrolizumab plus axitinib in patients with metastatic renal cell carcinoma.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the combination of pembrolizumab plus axitinib in the treatment of patients with metastatic renal cell carcinoma.

Investigators at Cleveland Clinic have demonstrated that the direct oral anticoagulant rivaroxaban significantly reduces venous thromboembolism (VTE) and VTE-related death for patients with high-risk cancers treated in the outpatient setting.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential for tivozanib in patients with advanced renal cell carcinoma.

Cleveland Clinic research has found that the blood thinner rivaroxaban significantly reduces venous thromboembolism (VTE)—a blood clot in the venous system—and VTE-related death for outpatient, high-risk cancer patients while they are taking the oral anticoagulant.

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.

Robert Dean, MD, staff physician, Cleveland Clinic, discusses challenges in the mantle cell lymphoma (MCL) paradigm.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses resistance to BTK inhibition in chronic lymphocytic leukemia (CLL).

Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.

Robert Dean, MD, a staff physician at Cleveland Clinic, discusses ongoing research on biomarkers in mantle cell lymphoma (MCL).

Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.

The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses the recent FDA approval of dose-adjusted carfilzomib in patients with myeloma.

Based on fresh studies in the setting of metastatic pancreatic cancer, the American Society of Clinical Oncology now recommends routine testing for mismatch repair deficiency or high microsatellite instability for candidates for checkpoint inhibitor therapy.

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.